Should You Buy HeartBeam, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, HeartBeam, Inc. (BEAT) scores 4.7/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.43, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 1 of 1 CirclFi valuation models project upside for HeartBeam, Inc. (BEAT) at $0.42 — the model consensus leans bullish, with a Quality Score of 4.7/10 and Value-Trap risk of 34/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for HeartBeam, Inc. (BEAT) in 2026?
What Is the Bull Case vs the Bear Case for HeartBeam, Inc. (BEAT)?
| Bull case — $0.43 target (+0.4%) | Bear case |
|---|---|
| No active model projects meaningful upside for BEAT at $0.42. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | No active model flags significant downside for BEAT. The Value Trap score of 34/100 still argues for some caution. |
How Does BEAT Compare to Its Health Information Services Peers?
Valuation data pages: ONMD · MSPR · VSEE · RVRC · WORX · VYND · SPOK · BTSG · DRIO · DOCS · HQY
Which Other Stocks Score Like BEAT on Quality?
Closest companies to BEAT’s Quality of Company score of 4.7/10, across all industries.
- SVRN — SVRN, Inc. (QOC 4.7) · analysis
- OWPC — One World Products, Inc. (QOC 4.7) · analysis
- PGOL — Patriot Gold Corp. (QOC 4.7) · analysis
- ZSTK — ZeroStack Corp. (QOC 4.7) · analysis
- ATVK — GlobalTek Ventures, Inc. (QOC 4.7) · analysis
- VANI — Vivani Medical, Inc. (QOC 4.7) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Health Information Services Screens Does BEAT Appear In?
So Is HeartBeam, Inc. (BEAT) Worth Buying in 2026?
HeartBeam, Inc. at $0.43 is a genuine coin-flip in our framework. The 0–0 bull-bear split across 1 models, +0.0% model spread, and median fair value of $0.43 (+0.4% vs price) argue for a watchlist position rather than a high-conviction bet. Quality at 4.7/10 adds additional caution to the mix.
These are quantitative model outputs, not investment recommendations. HeartBeam, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BEAT Stock?
Should I buy BEAT stock right now?
Based on CirclFi's multi-model analysis, 1 of 1 models see upside for BEAT at $0.42. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 4.7/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in HeartBeam, Inc.?
Key risks include: a below-average Quality Score of 4.7/10, indicating fundamental weakness; limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Health Information Services companies. Always diversify and consult a financial advisor.
How does BEAT compare to its competitors?
Among Health Information Services peers, BEAT holds a Quality Score of 4.7/10. Comparable companies include ONMD (QOC 4.8), MSPR (QOC 4.7), VSEE (QOC 4.8). The relative ranking helps investors identify whether BEAT offers better fundamental quality than alternatives in the same sector.
Is BEAT a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BEAT's Quality Score of 4.7/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy BEAT at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $0.43 to $0.43. At $0.42, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BEAT.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad